The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis
IntroductionOur meta-analysis aimed to evaluate the diagnostic value of 18F-DCFPyL prostate-specific membrane antigen (PSMA) PET in patients with suspected prostate cancer.MethodsWe searched for articles that evaluate the diagnostic value of 18F-DCFPyL PSMA PET in patients with suspected prostate ca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1145759/full |
| _version_ | 1811158942359748608 |
|---|---|
| author | Wenyang Pang Shulin Cheng Zhongbo Du Shuang Du |
| author_facet | Wenyang Pang Shulin Cheng Zhongbo Du Shuang Du |
| author_sort | Wenyang Pang |
| collection | DOAJ |
| description | IntroductionOur meta-analysis aimed to evaluate the diagnostic value of 18F-DCFPyL prostate-specific membrane antigen (PSMA) PET in patients with suspected prostate cancer.MethodsWe searched for articles that evaluate the diagnostic value of 18F-DCFPyL PSMA PET in patients with suspected prostate cancer in PubMed, Embase, Cochrane Library, and Web of Science until 1 August 2022. Using the QUADAS-2 instrument, two researchers independently assessed the effectiveness of the studies that were included. The four-grid table data were analyzed by Meta-disc1.4 and Stata 16.0 software. The heterogeneity of each study was tested.ResultsA total of five studies with 258 patients were included, and the pooled sensitivity and specificity of 18F-DCFPyL PSMA PET for primary prostate cancer were 0.92 (95% confidence interval (CI): 0.85–0.96) and 0.59 (95% CI: 0.08–0.96), respectively. 18F-DCFPyL PSMA PET was successful in detecting primary prostate cancer, with an area under the curve (AUC) of 0.92 (95% CI: 0.89–0.94).Conclusions18F-DCFPyL PSMA PET has a strong predictive value for primary prostate cancer and is an effective method for the non-invasive diagnosis of prostate cancer. More prospective articles were needed. |
| first_indexed | 2024-04-10T05:32:51Z |
| format | Article |
| id | doaj.art-dfa072a4ffe745ea93935af1d4761af1 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T05:32:51Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dfa072a4ffe745ea93935af1d4761af12023-03-07T06:03:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11457591145759The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysisWenyang Pang0Shulin Cheng1Zhongbo Du2Shuang Du3Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, ChinaDepartment of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, ChinaDepartment of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, ChinaDepartment of Dermatology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, ChinaIntroductionOur meta-analysis aimed to evaluate the diagnostic value of 18F-DCFPyL prostate-specific membrane antigen (PSMA) PET in patients with suspected prostate cancer.MethodsWe searched for articles that evaluate the diagnostic value of 18F-DCFPyL PSMA PET in patients with suspected prostate cancer in PubMed, Embase, Cochrane Library, and Web of Science until 1 August 2022. Using the QUADAS-2 instrument, two researchers independently assessed the effectiveness of the studies that were included. The four-grid table data were analyzed by Meta-disc1.4 and Stata 16.0 software. The heterogeneity of each study was tested.ResultsA total of five studies with 258 patients were included, and the pooled sensitivity and specificity of 18F-DCFPyL PSMA PET for primary prostate cancer were 0.92 (95% confidence interval (CI): 0.85–0.96) and 0.59 (95% CI: 0.08–0.96), respectively. 18F-DCFPyL PSMA PET was successful in detecting primary prostate cancer, with an area under the curve (AUC) of 0.92 (95% CI: 0.89–0.94).Conclusions18F-DCFPyL PSMA PET has a strong predictive value for primary prostate cancer and is an effective method for the non-invasive diagnosis of prostate cancer. More prospective articles were needed.https://www.frontiersin.org/articles/10.3389/fonc.2023.1145759/full18F-DCFPyL PSMA PETprostate cancerdiagnostic performancemeta-analysissystemic review and meta-analysis |
| spellingShingle | Wenyang Pang Shulin Cheng Zhongbo Du Shuang Du The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis Frontiers in Oncology 18F-DCFPyL PSMA PET prostate cancer diagnostic performance meta-analysis systemic review and meta-analysis |
| title | The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis |
| title_full | The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis |
| title_fullStr | The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis |
| title_full_unstemmed | The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis |
| title_short | The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis |
| title_sort | diagnostic performance of 18f dcfpyl pet in patients with suspected prostate cancer a systemic review and meta analysis |
| topic | 18F-DCFPyL PSMA PET prostate cancer diagnostic performance meta-analysis systemic review and meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1145759/full |
| work_keys_str_mv | AT wenyangpang thediagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis AT shulincheng thediagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis AT zhongbodu thediagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis AT shuangdu thediagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis AT wenyangpang diagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis AT shulincheng diagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis AT zhongbodu diagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis AT shuangdu diagnosticperformanceof18fdcfpylpetinpatientswithsuspectedprostatecancerasystemicreviewandmetaanalysis |